Zhangrong Jia

Dr. Zhangrong Jia

orcid

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
14 May 2021 in Medicine
Verified
Journal Article
Open access
ZJZhangrong Jia
Zhangrong Jia
YZYue’An Zhang
Yue’An Zhang
JDJunping Deng
Junping Deng
YGYanqing Guo
Yanqing Guo
YDYimei Du
Yimei Du
ZJZhangrong Jia
Zhangrong Jia
It is well known that many genetic factors are involved in the occurrence and progression of atrioventricular block (AV block) and atrial fibrillation (AF). However, the genetic variants discovered so far have only explained parts of these processes. More genes and variants remain to be identified. In the present study, a three-generation family with an autosomal dominant form of AV block and AF was enrolled. Whole exome sequencing was conducted in three affected and one unaffected family member. A total of 64 nonsynonymous variants was shared by three affected individuals and not present in the unaffected individual. By selection of variants absent in the known databases and were predicted to be deleterious, 4 novel variants were identified. Only one novel frameshift insertion in the LMNA gene (c.825_826insCAGG) was identified in another affected family member and not detected in other non-affected family members and the 100 controls. Our finding expanded the spectrum of variants associated with AV block and AF, and was valuable in the genetic diagnosis of AV block and AF.

17 April 2025 in Molecules
Verified
Journal Article
Open access
PDF file
JCJiasong Chang
Jiasong Chang
YLYang xiu Long
Yang xiu Long
TZTong Zhang
Tong Zhang
SHSun Hao
Sun Hao
HCHongying Cheng
Hongying Cheng
DWDe-Ping Wang
De-Ping Wang
Genome editing is a promising therapeutic strategy for genetic disorders by modifying the genome precisely, especially the CRISPR/Cas9 system. However, a major limitation of CRISPR/Cas9 in gene therapy is the biosafety issues caused by off-target effects. Compounds that can modulate the genome editing efficiency of the CRISPR/Cas9 system, especially those reducing the off-target effects, are potentially useful pharmacological tools for improving the effectiveness and safety of genome editing. Here, we performed high-throughput screening in HEK 293FT cells to discover compounds that decrease or increase the genome editing efficiency of the CRISPR/Cas9 system from 9930 compounds. After two rounds of screening, we identified that CP-724714, a ErbB2 (HER2) tyrosine kinase inhibitor, decreased the CRISPR/Cas9 efficiency and reduced the off-target effects by suppressing the efficiency of CRISPR/Cas9, and was thus named a CRISPR decelerator (or inhibitor), while Clofarabine, a DNA synthesis inhibitor, increased the efficiency of CRISPR/Cas9, and was named a CRISPR accelerator. We further identified four compounds (Tranilast, Cerulenin, Rosolic acid and Resveratrol) that affected the efficiency of single-strand annealing (SSA) repair. Among them, Tranilast, Cerulenin and Rosolic acid are potential SSA decelerators, while Resveratrol is a potential SSA accelerator. These identified compounds may be useful in optimizing mammalian genetic manipulation techniques.

23 August 2025 in Archives of Medical Science
Verified
Journal Article
Open access
ZJZhangrong Jia
Zhangrong Jia
NLNa Li
Na Li
JCJiasong Chang
Jiasong Chang
SZsheng xiao zhang
sheng xiao zhang
HWHaixiong Wang
Haixiong Wang
DWDe-Ping Wang
De-Ping Wang